Mersana Therapeutics sell quelbe60
Start price
12.11.24
/
50%
€2.00
Target price
12.11.25
-
Performance (%)
-0.70%
End price
23.11.24
€1.99
Summary
This prediction ended on 23.11.24 with a price of €1.99. From the start of the prediction for Mersana Therapeutics the price only changed by -0.70%. quelbe60 has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Mersana Therapeutics | - | - | - |
| iShares Core DAX® | 0.795% | 1.458% | 17.980% |
| iShares Nasdaq 100 | -3.088% | -0.762% | 3.169% |
| iShares Nikkei 225® | -0.952% | -2.268% | 12.208% |
| iShares S&P 500 | -1.393% | 0.199% | 1.698% |
According to quelbe60 what are the pros and cons of Mersana Therapeutics for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Cons
Comments by quelbe60 for this prediction
In the thread Mersana Therapeutics diskutieren
Sell Mersana Therapeutics
In the thread Trading Mersana Therapeutics
Sell beendet
Stopped prediction by quelbe60 for Mersana Therapeutics
Mersana Therapeutics
Start price
Target price
Perf. (%)
€1.35
01.09.24
01.09.24
-
01.09.25
01.09.25
40.33%
16.09.24
16.09.24
Could be very worthwhile Investment >20% year
Mersana Therapeutics
Start price
Target price
Perf. (%)
€1.37
04.08.24
04.08.24
-
04.08.25
04.08.25
-13.20%
18.08.24
18.08.24
Could be very worthwhile Investment >20% year
Mersana Therapeutics
Start price
Target price
Perf. (%)
€1.61
06.07.24
06.07.24
-
06.07.25
06.07.25
22.79%
17.07.24
17.07.24
Could be very worthwhile Investment >20% year
Mersana Therapeutics
Start price
Target price
Perf. (%)
€2.43
12.05.24
12.05.24
-
12.05.25
12.05.25
-11.73%
24.05.24
24.05.24
Could be very worthwhile Investment >20% year
Mersana Therapeutics
Start price
Target price
Perf. (%)
€1.11
21.08.23
21.08.23
-
21.08.24
21.08.24
0.27%
30.08.23
30.08.23
Could be very worthwhile Investment >20% year
Mersana Therapeutics
Start price
Target price
Perf. (%)
€1.25
27.07.23
27.07.23
-
27.07.24
27.07.24
-31.70%
27.07.23
27.07.23
Could be very worthwhile Investment >20% year

